Brind.

AbbVie and ReGenX Biosciences entered into a collaboration regarding the development of treatments for diabetic retinopathy.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbbVie ReGenX Biosciences (United States)

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
ReGenX Biosciences (United States)
company in Washington D.C., United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 7PR NewswireREGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will b